Advancing Neurological Disease Treatment through the Integration of Precision Medicine and Neurogenetics
Shamsuddin Sultan Khan 1*, John A Catanzaro 1, Wei Zhang 1
Journal of Precision Biosciences 3(1) 1-8 https://doi.org/10.25163/biosciences.3120042
Submitted: 03 March 2021 Revised: 19 May 2021 Published: 20 May 2021
Abstract
Neurogenetics, at the intersection of neurobiology and genetics, plays a crucial role in understanding the complex biological foundations of neurological disorders. As our knowledge of the genetic underpinnings of these conditions advances, the potential for personalized treatments grows significantly. This abstract explores the synergistic relationship between precision medicine and neurogenetics, emphasizing their transformative potential for treating a broad range of neurological diseases. Genetic factors play a key role in the onset, progression, and manifestation of disorders such as neuromuscular diseases, epilepsy, and neurodegenerative conditions like Parkinson’s and Alzheimer’s. Recent advancements in genomic technologies have enabled researchers to identify specific genetic variations linked to these diseases, offering a more detailed understanding of the genetic network influencing brain function. The integration of precision medicine with neurogenetics is revolutionizing therapeutic approaches. By leveraging an individual’s genetic profile, precision therapies tailor interventions to target the root causes of neurological conditions, offering a more effective alternative to conventional treatments, which often have limited success due to the heterogeneous nature of these disorders. Through the exploration of genetic complexities, new therapeutic targets are emerging, and innovative treatments, including gene therapies and customized medications, are being developed. This approach not only enhances treatment efficacy but also minimizes side effects, shifting the focus toward personalized, patient-centered care. In conclusion, the fusion of precision medicine and neurogenetics is poised to open a new chapter in the management of neurological diseases. With ongoing technological advancements and a deeper understanding of genetics, the potential to improve patient outcomes and revolutionize treatment approaches by tailoring therapies to individual genetic profiles is vast.
Keywords: Neurogenetics,. Precision treatments, Neurological disorders, Genetic factors, Personalized interventions
References
Adhikari, A. N., Gallagher, R. C., Wang, Y., Currier, R. J., Amatuni, G., Bassaganyas, L., ... & Brenner, S. E. (2020). The role of exome sequencing in newborn screening for inborn errors of metabolism. Nature medicine, 26(9), 1392-1397.
Annemans, L., Aymé, S., Le Cam, Y., Facey, K., Gunther, P., Nicod, E., ... & Le Dez, L. (2017). Recommendations from the European working Group for Value Assessment and Funding Processes in rare diseases (ORPH-VAL). Orphanet journal of rare diseases, 12, 1-15.
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., ... & Reeves, R. H. (2020). Down syndrome. Nature Reviews Disease Primers, 6(1), 9.
Barendsen, R. W., Dijkstra, I. M., Visser, W. F., Alders, M., Bliek, J., Boelen, A., ... & Kemp, S. (2020). Adrenoleukodystrophy newborn screening in the Netherlands (SCAN Study): the X-factor. Frontiers in Cell and Developmental Biology, 8, 499.
Bianchi, M. L., & Vai, S. (2019). Alkaline phosphatase replacement therapy. Therapeutic Enzymes: Function and Clinical Implications, 201-232.
Blau, N., Duran, M., Gibson, K. M., & Dionisi-Vici, C. (Eds.). (2014). Physician's guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases (Vol. 213). Berlin/Heidelberg: Springer.
Bok, L. A., Halbertsma, F. J., Houterman, S., Wevers, R. A., Vreeswijk, C., Jakobs, C., ... & Willemsen, M. A. (2012). Long-term outcome in pyridoxine-dependent epilepsy. Developmental Medicine & Child Neurology, 54(9), 849-854.
Boycott, K. M., & Ardigó, D. (2018). Addressing challenges in the diagnosis and treatment of rare genetic diseases. Nature Reviews Drug Discovery, 17(3), 151-152.
Boycott, K. M., Campeau, P. M., Howley, H. E., Pavlidis, P., Rogic, S., Oriel, C., ... & Hieter, P. (2020). The Canadian rare diseases models and mechanisms (RDMM) network: connecting understudied genes to model organisms. The American Journal of Human Genetics, 106(2), 143-152.
Budimirovic, D. B., Berry-Kravis, E., Erickson, C. A., Hall, S. S., Hessl, D., Reiss, A. L., ... & Kaufmann, W. E. (2017). Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. Journal of Neurodevelopmental Disorders, 9(1), 1-36.
Cakici, J. A., Dimmock, D. P., Caylor, S. A., Gaughran, M., Clarke, C., Triplett, C., ... & Bloss, C. S. (2020). A prospective study of parental perceptions of rapid whole-genome and-exome sequencing among seriously ill infants. The American Journal of Human Genetics, 107(5), 953-962.
Camfield, P., & Camfield, C. (2011). Transition to adult care for children with chronic neurological disorders. Annals of neurology, 69(3), 437-444.
Centerwall, S. A., & Centerwall, W. R. (2000). The discovery of phenylketonuria: the story of a young couple, two retarded children, and a scientist. Pediatrics, 105(1), 89-103.
Coppus, A. M. (2013). People with intellectual disability: what do we know about adulthood and life expectancy?. Developmental disabilities research reviews, 18(1), 6-16.
Coughlin II, C. R., van Karnebeek, C. D., Al-Hertani, W., Shuen, A. Y., Jaggumantri, S., Jack, R. M., ... & Van Hove, J. L. (2015). Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: neurodevelopmental outcome. Molecular Genetics and Metabolism, 116(1-2), 35-43.
Coughlin, C. R., Tseng, L. A., Abdenur, J. E., Ashmore, C., Boemer, F., Bok, L. A., ... & van Karnebeek, C. D. (2021). Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. Journal of inherited metabolic disease, 44(1), 178-192.
Demos, M., Guella, I., DeGuzman, C., McKenzie, M. B., Buerki, S. E., Evans, D. M., ... & Farrer, M. J. (2019). Diagnostic yield and treatment impact of targeted exome sequencing in early-onset epilepsy. Frontiers in neurology, 10, 434.
Den Hollander, B., Rasing, A., Post, M. A., Klein, W. M., Oud, M. M., Brands, M. M., ... & van Karnebeek, C. D. (2021). NANS-CDG: delineation of the genetic, biochemical, and clinical spectrum. Frontiers in Neurology, 681.
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., ... & Williams, D. A. (2017). Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. New England Journal of Medicine, 377(17), 1630-1638.
Engelke, U. F., Van Outersterp, R. E., Merx, J., Van Geenen, F. A., Van Rooij, A., Berden, G., ... & Coene, K. L. (2021). Untargeted metabolomics and infrared ion spectroscopy identify biomarkers for pyridoxine-dependent epilepsy. The Journal of clinical investigation, 131(15).
Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., ... & Berry-Kravis, E. (2017). Fragile X targeted pharmacotherapy: lessons learned and future directions. Journal of neurodevelopmental disorders, 9(1), 1-14.
Falkenberg, K. D., Braverman, N. E., Moser, A. B., Steinberg, S. J., Klouwer, F. C., Schlüter, A., ... & Waterham, H. R. (2017). Allelic expression imbalance promoting a mutant PEX6 allele causes Zellweger spectrum disorder. The American Journal of Human Genetics, 101(6), 965-976.
Ferreira, C. R., Rahman, S., Keller, M., Zschocke, J., ICIMD Advisory Group, Abdenur, J., ... & Zeviani, M. (2021). An international classification of inherited metabolic disorders (ICIMD). Journal of inherited metabolic disease, 44(1), 164-177.
Ferreira, C. R., van Karnebeek, C. D., Vockley, J., & Blau, N. (2019). A proposed nosology of inborn errors of metabolism. Genetics in medicine, 21(1), 102-106.
Kotulska, K., Kwiatkowski, D. J., Curatolo, P., Weschke, B., Riney, K., Jansen, F., ... & Wojdan, K. (2021). Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Annals of neurology, 89(2), 304-314.
Kremer, L. S., Bader, D. M., Mertes, C., Kopajtich, R., Pichler, G., Iuso, A., ... & Prokisch, H. (2017). Genetic diagnosis of Mendelian disorders via RNA sequencing. Nature communications, 8(1), 15824.
Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., ... & Franz, D. N. (2010). Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New England Journal of Medicine, 363(19), 1801-1811.
Lee, J. J., Wasserman, W. W., Hoffmann, G. F., Van Karnebeek, C. D., & Blau, N. (2018). Knowledge base and mini-expert platform for the diagnosis of inborn errors of metabolism. Genetics in Medicine, 20(1), 151-158.
Mueller, T., Jerrentrup, A., Bauer, M. J., Fritsch, H. W., & Schaefer, J. R. (2016). Characteristics of patients contacting a center for undiagnosed and rare diseases. Orphanet Journal of Rare Diseases, 11(1), 1-9.
Müller, A. R., Brands, M. M., van de Ven, P. M., Roes, K. C., Cornel, M. C., van Karnebeek, C. D., ... & van Eeghen, A. M. (2021). Systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders: the power of 1. Neurology, 96(11), 529-540.
Overwater, I. E., Rietman, A. B., Mous, S. E., Bindels-de Heus, K., Rizopoulos, D., Ten Hoopen, L. W., ... & de Wit, M. C. Y. (2019). A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex. Neurology, 93(2), e200-e209.
Petrikin, J. E., Willig, L. K., Smith, L. D., & Kingsmore, S. F. (2015, December). Rapid whole genome sequencing and precision neonatology. In Seminars in perinatology (Vol. 39, No. 8, pp. 623-631). WB Saunders.
Posey, J. E., Harel, T., Liu, P., Rosenfeld, J. A., James, R. A., Coban Akdemir, Z. H., ... & Lupski, J. R. (2017). Resolution of disease phenotypes resulting from multilocus genomic variation. New England Journal of Medicine, 376(1), 21-31.
Quaio, C. R. D. A. C., Moreira, C. M., Novo-Filho, G. M., Sacramento-Bobotis, P. R., Groenner Penna, M., Perazzio, S. F., ... & Baratela, W. A. D. R. (2020, December). Diagnostic power and clinical impact of exome sequencing in a cohort of 500 patients with rare diseases. In American Journal of Medical Genetics Part C: Seminars in Medical Genetics (Vol. 184, No. 4, pp. 955-964). Hoboken, USA: John Wiley & Sons, Inc..
Richmond, P. A., Van der Kloet, F., Vaz, F. M., Lin, D., Uzozie, A., Graham, E., ... & van Karnebeek, C. D. (2020). Multi-omic approach to identify phenotypic modifiers underlying cerebral demyelination in X-linked adrenoleukodystrophy. Frontiers in cell and developmental biology, 8, 520.
Rosso, M., Fremion, E., Santoro, S. L., Oreskovic, N. M., Chitnis, T., Skotko, B. G., & Santoro, J. D. (2020). Down syndrome disintegrative disorder: a clinical regression syndrome of increasing importance. Pediatrics, 145(6).
Sadikovic, B., Levy, M. A., Kerkhof, J., Aref-Eshghi, E., Schenkel, L., Stuart, A., ... & Alders, M. (2021). Clinical epigenomics: genome-wide DNA methylation analysis for the diagnosis of Mendelian disorders. Genetics in Medicine, 23(6), 1065-1074.
Sahin, M., & Sur, M. (2015). Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science, 350(6263), aab3897.
Satterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J. Y., ... & Demontis, D. (2020). Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell, 180(3), 568-584.
Schenkel, L. C., Kernohan, K. D., McBride, A., Reina, D., Hodge, A., Ainsworth, P. J., ... & Sadikovic, B. (2017). Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome. Epigenetics & chromatin, 10, 1-11.
Senn, S. (2016). Mastering variation: variance components and personalised medicine. Statistics in medicine, 35(7), 966-977.
Senn, S. (2019). Sample size considerations for n-of-1 trials. Statistical methods in medical research, 28(2), 372-383.
Slade, A., Isa, F., Kyte, D., Pankhurst, T., Kerecuk, L., Ferguson, J., ... & Calvert, M. (2018). Patient reported outcome measures in rare diseases: a narrative review. Orphanet journal of rare diseases, 13, 1-9.
Tarailo-Graovac, M., Shyr, C., Ross, C. J., Horvath, G. A., Salvarinova, R., Ye, X. C., ... & van Karnebeek, C. D. (2016). Exome sequencing and the management of neurometabolic disorders. New England Journal of Medicine, 374(23), 2246-2255.
van Karnebeek, C. D., & Jaggumantri, S. (2015). Current treatment and management of pyridoxine-dependent epilepsy. Current treatment options in neurology, 17, 1-12.
Vissers, L. E., Gilissen, C., & Veltman, J. A. (2016). Genetic studies in intellectual disability and related disorders. Nature Reviews Genetics, 17(1), 9-18.
Wagstaff, E. L., Ten Asbroek, A. L., Ten Brink, J. B., Jansonius, N. M., & Bergen, A. A. (2021). An alternative approach to produce versatile retinal organoids with accelerated ganglion cell development. Scientific Reports, 11(1), 1101.
Wanders, R. J., Vaz, F. M., Ferdinandusse, S., van Kuilenburg, A. B., Kemp, S., van Karnebeek, C. D., ... & Houtkooper, R. H. (2019). Translational Metabolism: A multidisciplinary approach towards precision diagnosis of inborn errors of metabolism in the omics era. Journal of inherited metabolic disease, 42(2), 197-208.
Warmerdam, H. A., Termeulen-Ferreira, E. A., Tseng, L. A., Lee, J. Y., van Eeghen, A. M., Ferreira, C. R., & van Karnebeek, C. D. (2020). A scoping review of inborn errors of metabolism causing progressive intellectual and neurologic deterioration (PIND). Frontiers in neurology, 10, 1369.
Zapata-Pérez, R., Wanders, R. J., van Karnebeek, C. D., & Houtkooper, R. H. (2021). NAD+ homeostasis in human health and disease. EMBO molecular medicine, 13(7), e13943.
View Dimensions
View Altmetric
Save
Citation
View
Share